{"entity":{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","aka":[],"tldr":"Kumquat Biosciences is a San Diego company founded by KRAS pioneers that makes pills against the KRAS cancer protein and immune-boosting small molecules. Its KRAS G12D drug entered human trials with Bayer in 2025.","summary":"Kumquat Biosciences is a clinical-stage San Diego biotechnology company founded in 2018 by pioneers of KRAS targeting. Its lead asset, KQB548 (BAY 3771249), is a KRAS G12D inhibitor licensed to Bayer in August 2025 in a deal worth up to 1.3 billion US dollars in upfront and milestone payments plus royalties; a first-in-human phase 1 monotherapy trial (NCT07207707) in KRAS G12D-mutant tumours such as pancreatic, colorectal and lung cancer began in October 2025. Kumquat also granted Takeda an exclusive global licence to an oral immuno-oncology small molecule (up to 130 million US dollars near term and more than 1.2 billion in potential milestones) and has a discovery collaboration with Lilly on small molecules that stimulate tumour-specific immune responses. SEC Form D filings show about 56 million US dollars sold in 2019 and a further 80 million US dollars sold in 2021; round names are not disclosed.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://kumquatbiosciences.com/"},{"label":"Bayer licence and collaboration (August 2025)","url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-enter-global-exclusive-license-and-collaboration-in-precision-oncology/"},{"label":"Phase 1 start with Bayer (October 2025)","url":"https://kumquatbiosciences.com/news/bayer-and-kumquat-biosciences-initiate-phase-i-study-with-kras-g12d-inhibitor-in-patients-with-kras-mutated-tumors/"},{"label":"Takeda collaboration","url":"https://kumquatbiosciences.com/news/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate/"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07406633"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Stage set to startup because no round beyond the 2021 Form D offerings was found; series labels and investors are not disclosed in fetched sources."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://kumquatbiosciences.com/","founded":2018,"stage":"startup","investors":[],"funding":[{"round":"Form D offering","year":2019,"amountUsd":55922930,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000178182219000002/primary_doc.xml","note":"Total sold per amended Form D filed August 2019"},{"round":"Form D offering","year":2021,"amountUsd":50000000,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000184161321000002/primary_doc.xml","note":"Total sold per Form D filed February 2021"},{"round":"Form D offering","year":2021,"amountUsd":30000012,"source":"https://www.sec.gov/Archives/edgar/data/1781822/000184161321000008/primary_doc.xml","note":"Total sold per amended Form D filed August 2021"}]},"route":"/companies/kumquat-biosciences/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"trial":[{"id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/"}]}}